Novavax, Inc. signed a non-exclusive, worldwide license agreement with Wyeth for the rights to a patent application covering virus-like particle (VLP) technology for vaccines. The agreement includes an upfront payment, annual license fees, milestone payments and royalties on any product sales. Payments to Wyeth could total $5 million through 2008. Novavax is developing pandemic and seasonal flu vaccines based on the VLP technology. VLPs mimic the three-dimensional structure of a virus but d...